| 2021-04-27 |
详情>>
拆分方案：
每6.0000合并分成1.0000股
|
| 2021-04-02 |
热点提醒：
美股因复活节假期，4月2日休市一天
|
| 2021-03-22 |
详情>>
业绩披露：
2020年年报每股收益-1.17美元,归母净利润-1626.68万美元,同比去年增长-94.77%
|
| 2021-02-11 |
股东大会：
将于2021-03-24召开股东大会
会议内容 ▼▲
- 1.Approve an amended and restated certificate of incorporation of Seneca to effect a reverse stock split of Seneca Common Stock at a ratio within the range not less than 1-for-5 and not greater than 1-for-12 (with such ratio to be mutually agreed upon by Seneca and LBS prior to the effectiveness of the Merger);
2.Approve (i) the issuance of shares of Seneca Common Stock pursuant to the Merger and Pre-Merger Financing, which will represent more than 20% of the shares of Seneca Common Stock outstanding immediately prior to the Merger, and (ii) the change of control resulting from the Merger and Pre-Merger Financing, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively;
3.Approve the Palisade Bio, Inc. 2021 Equity Incentive Plan;
4.Approve the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan;
5.Approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Seneca’s named executive officers in connection with the completion of the Merger, including the agreements and understandings pursuant to which such compensation may be paid or become payable;
6.Approve a postponement or adjournment of the Seneca virtual special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposals set forth above.
|
| 2020-12-17 |
复牌提示：
2020-12-17 07:00:19 停牌，复牌日期 2020-12-17 07:30:00
|
| 2020-11-10 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-0.93美元,归母净利润-1184.8万美元,同比去年增长-87.64%
|
| 2020-08-13 |
详情>>
股本变动：
变动后总股本1729.57万股
变动原因 ▼▲
- 原因：
- From March 31, 2020 to June 30, 2020
Issuance of common stock and warrants from capital raises, net
Issuance of common stock from exercise of warrants
Issuance of common stock from RSU conversions
Forfeiture of restricted stock awards
|
| 2020-08-13 |
详情>>
业绩披露：
2020年中报每股收益-0.92美元,归母净利润-952.62万美元,同比去年增长-109.32%
|
| 2020-08-10 |
股东大会：
将于2020-08-07召开股东大会
会议内容 ▼▲
- 1.To elect two Class III directors to hold office until the 2023 annual meeting of stockholders or until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2.To ratify the appointment of Dixon Hughes Goodman LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To ratify the filing and effectiveness of the amendment to the Company’s amended and restated certificate of incorporation that was filed with the Secretary of State of the State of Delaware on July 10, 2019 (the “2019 Reverse Stock Split Amendment”) and the effectiveness of the 1-for-20 reverse stock split effected thereby on July 17, 2019 (the “2019 Reverse Stock Split”);
4.To approve an amendment to the Company’s amended and restated certificate of incorporation to authorize the Board of Directors (the “Board”) of the Company to effect a reverse split of the Company’s issued and outstanding common stock (“Common Stock”) by a ratio of not less than 1-for-2 and not more than 1-for-25, with the Board having the discretion as to whether or not the reverse stock split is to be effected at any time prior to the first anniversary date of this Annual Meeting, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board in its sole discretion;
5.An advisory vote to approve executive compensation (non-binding);
6.An advisory vote to approve the frequency of holding future advisory votes on executive compensation every 1, 2 or 3 years (non-binding);
7.To approve the Seneca Biopharma 2020 Equity Incentive Plan (“2020 Plan”) and the conditional grants made thereunder to date;
8.To transact any other business that properly comes before the Annual Meeting (including adjournments, continuations, and postponements thereof).
|
| 2020-08-10 |
股东大会：
将于2020-09-04召开股东大会
会议内容 ▼▲
- 1.To ratify the filing and effectiveness of the amendment to the Company’s amended and restated certificate of incorporation that was filed with the Secretary of State of the State of Delaware on July 10, 2019 (the “2019 Reverse Stock Split Amendment”) and the effectiveness of the 1-for-20 reverse stock split effected thereby on July 17, 2019 (the “2019 Reverse Stock Split”);
2.To approve an amendment to the Company’s amended and restated certificate of incorporation to authorize the Board of Directors (the “Board”) of the Company to effect a reverse split of the Company’s issued and outstanding common stock (“Common Stock”) by a ratio of not less than 1-for-2 and not more than 1-for-25, with the Board having the discretion as to whether or not the reverse stock split is to be effected at any time prior to the first anniversary date of this Annual Meeting, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board in its sole discretion;
3.To approve the Seneca Biopharma 2020 Equity Incentive Plan (“2020 Plan”) and the conditional grants made thereunder to date;
|
| 2020-05-15 |
详情>>
业绩披露：
2020年一季报每股收益-0.93美元,归母净利润-757.52万美元,同比去年增长-143.26%
|
| 2020-03-27 |
详情>>
业绩披露：
2019年年报每股收益-3.8美元,归母净利润-835.17万美元,同比去年增长-69.59%
|
| 2019-11-14 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-4.8美元,归母净利润-631.4万美元,同比去年增长-37.13%
|